Behring Institute

CSL Behring is a global leader in the biotherapeutics industry, specializing in the development and manufacture of therapies for rare and serious diseases. The company's extensive portfolio includes plasma-derived and recombinant products for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, and respiratory conditions. CSL Behring is notably the provider of Hemgenix, the first gene therapy for Hemophilia B. Headquartered in King of Prussia, Pennsylvania, it operates as a major subsidiary of CSL Limited, continuing the legacy of the historical Behringwerke research institute founded by Nobel laureate Emil von Behring.